|
|
||||||||


* Laboratory of Immunopharmacology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; and
Department of Oncology and Neurosciences, G dAnnunzio University, Chieti, Italy
IL-12 and IL-15 stimulate T, B, and NK cell functions through independent mechanisms, and cooperative effects of these cytokines have been reported. The human MHC class I-negative small cell lung cancer cell line, N592, genetically engineered to secrete IL-15, N592/IL-15, showed a reduced tumor growth rate, while N592 cells engineered with IL-12, N592/IL-12, grew similarly to the wild-type N592, N592 parental cells (N592pc), in nude mice. However, N592 cells coexpressing both cytokines, N592/IL-12/IL-15 cells, were completely rejected by 100% of nude mice. Here we show that 60% of nude mice rejecting N592/IL-12/IL-15 cells were resistant to N592pc rechallenge. SCID mice rejected N592/IL-12/IL-15 cells, but did not develop resistance to N592pc rechallenge, suggesting a role of Ab responses. Among nude mice rejecting N592/IL-12/IL-15 cells, those developing resistance to N592pc rechallenge had significantly higher titers of anti-N592 IgG2b Abs than nonresistant nude mice. Induction of an Ig class switch in nude mice was related to the expression of IFN-
and CD40 ligand in the draining lymph nodes. An IgG2b, anti-N592 mAb, derived from N592/IL-12/IL-15-immunized nude mice splenocytes induced significant protection against N592pc, while an IgM mAb was ineffective. The protective IgG2b mAb, but not the IgM mAb, triggered Ab-dependent cell-mediated cytotoxicity by nude mouse splenocytes against N592pc. These data indicate that IL-12 and IL-15 synergistically trigger innate, immunity-mediated, anti-tumor effects, resulting in cytotoxic IgG Ab responses in T cell-deficient mice. Protective Ab responses may relate to both direct actions of IL-12 and IL-15 on B cells and to the activation of an innate immunity-B cell cross-talk.
This article has been cited by other articles:
![]() |
A. K. Simon, T. Newsom-Davis, M. E. F. Frayne, P. F.-T. Ch'en, A. J. McMichael, and G. R. Screaton Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies using melanoma modified with Fas ligand Int. Immunol., April 1, 2008; 20(4): 525 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tsuchiyama, Y. Nakamoto, Y. Sakai, Y. Marukawa, M. Kitahara, N. Mukaida, and S. Kaneko Prolonged, NK Cell-Mediated Antitumor Effects of Suicide Gene Therapy Combined with Monocyte Chemoattractant Protein-1 against Hepatocellular Carcinoma J. Immunol., January 1, 2007; 178(1): 574 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sun, H. Wei, R. Sun, W. Xiao, Y. Yang, and Z. Tian Human Interleukin-15 Improves Engraftment of Human T Cells in NOD-SCID Mice Clin. Vaccine Immunol., February 1, 2006; 13(2): 227 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Li, A. C. Grover, E. J. Donald, A. Carr, J. Yu, J. Whitfield, M. Nelson, N. Takeshita, and A. E. Chang Simultaneous Targeting of CD3 on T Cells and CD40 on B or Dendritic Cells Augments the Antitumor Reactivity of Tumor-Primed Lymph Node Cells J. Immunol., August 1, 2005; 175(3): 1424 - 1432. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ing, P. Gros, and M. M. Stevenson Interleukin-15 Enhances Innate and Adaptive Immune Responses to Blood-Stage Malaria Infection in Mice Infect. Immun., May 1, 2005; 73(5): 3172 - 3177. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |